Gala Therapeutics Announces First Patients Enrolled in Pivotal Trial of RheOx™ System for Chronic Bronchitis

SAN CARLOS, Calif., May 20, 2021 /PRNewswire/ — Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, has initiated its pivotal clinical trial to evaluate its RheOx™ Bronchial Rheoplasty System for the treatment of the symptoms of chronic bronchitis.

…

Doug Godshall to Chair Gala Therapeutics Board of Directors

San Carlos, CA, March 2, 2021 – Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat chronic bronchitis and other pulmonary diseases, announced today that it has appointed Douglas Godshall to chair of its Board of Directors.

…

Gala Therapeutics Receives FDA Approval to Commence Pivotal Trial to Evaluate the RheOx^TM System for Chronic Bronchitis

San Carlos, CA – Feb. 22, 2021 – Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, announces U.S. Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to commence its pivotal clinical trial called RheSolve,

…

Gala Therapeutics’ RheOx^TM System Showcased in Live Case at Virtual European Respiratory Society (ERS) Congress as Part of Post-Market Chronic Bronchitis Study

Menlo Park, CA, Sept. 9, 2020 – Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced that a live case featuring its RheOx^TM Bronchial Rheoplasty System was performed during the virtual European Respiratory Society (ERS) International Congress 2020.

…

Gala Therapeutics Announces Publication of Multicenter Study of the Minimally Invasive RheOx^TM System in Patients with Chronic Bronchitis

​New Clinical Results from RheOx^TM System for Chronic Bronchitis to be Presented at European Respiratory Society (ERS) International Congress

Menlo Park, Calif. – Sept. 26, 2019 – Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced that clinical results and a patient case involving its RheOx^TM Bronchial Rheoplasty system will be presented at the 2019 ERS International Congress,

…

Gala Therapeutics Receives FDA Breakthrough Device Designation for the Minimally Invasive RheOx^TM System for Chronic Bronchitis

Menlo Park, CA Sept. 16, 2019 – Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation (FDA) for the RheOx^TM Bronchial Rheoplasty^TM system.

…

Gala Therapeutics Receives CE Mark for its Minimally Invasive RheOx^TM System for Chronic Bronchitis

First-of-its-kind RheOx device designed to reduce mucus-producing cells and improve quality of life 

Menlo Park, CA Sept. 4, 2019 – Gala Therapeutics, Inc. (Gala) today announced that its RheOx^TM system has received CE Mark in the European Union.

…

Initial Study of the Minimally Invasive RheOx^TM Device Demonstrates Positive Results for Chronic Bronchitis Patients

Dallas, Texas, May 22, 2019 – Gala Therapeutics, Inc. (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced new results from the initial study of its investigational RheOx^TM device,

…

New Data from First-in-Human Study of RheOx^TM Device-Based Therapy for Chronic Bronchitis to be Presented at ATS 2019

Menlo Park, Calif., May 16, 2019 – Gala Therapeutics, Inc. (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that data from the first-in-human study of its investigational RheOx^TM device will be presented at the 2019 American Thoracic Society (ATS) International Conference,

…